Patients (pts) with germinal
We conducted a retrospective, multicentre observational study to assess the benefit of PARPi post-PBC and viceversa in pts with g
59 pts from 5 centers were included. Pts characteristics and outcomes are reported in the table. PARPi-mPFS in metastatic setting of pts from Gr1 (N=9) was 4.8 months (mo). DCR was of 67%. In Gr2 (N=31), mPFS with PBC and subsequent PARPi were 4.3 and 4.5 mo; DCRs were of 97% and 45%. Age<46 and platinum free interval (PFI)>6mo were associated with longer PARPi-PFS (p=.009 and .016). PBC-PFS>6mo and PFI>6mo were associated with longer PARPi-DCR (p=.031 and .032). Pts in Gr3 (N=21) reported a mPFS of 5.0 with PARPi and 1.8 mo with subsequent PBC, DCRs were of 67 and 14%. PARPi in earlier lines (1-2) was associated with longer PBC-PFS (p=.020). PARPi-PFS>9mo and PARPi-FI>6mo were associated with longer PBC-DCR (p=.015 and .026).
Pts characteristics and outcomes NA: not applicable; (NA)-PBC: (neoadjuvant) platinum-based chemotherapy; TNBC: triple negative BC
Gr1 (N=9) Gr2 (N=31) Gr3 (N=21) Age at diagnosis – median (range) 38 (29-62) 40 (28-72) 39 (28-62) Visceral disease – % 67% 81% 86% 0% 13% 24% BRCA1/BRCA2/NA – % 56/44/0% 48/39/13% 29/62/10% TNBC/Luminal-like – % 67/33% 52/48% 33/67% PARP line (1-2/>2) – % 67/33% 29/71% 5/95% N. of line – median (range) NA 2 (2-5) 2 (1-10) 3 (2-12) 3 (1-11) 4 (2-13) PFS – median (range) NA 4.8 (0.9-25.4) 4.3 (1.5-23.8) 4.5 (0.3-35.7) 5.0 (0.9-12.4) 1.8 (0.1-5.0) DCR – % NA 67% 97% 45% 67% 14%
Sensitivity and resistance to PARPi and PBC partially overlap in BC. mPFS on PBC/PARPi and PFI/PARPi-FI represent two potential predictive factors of DCR for the subsequent treatment with PARPi/PBC.
The authors.
Has not received any funding.
R. Berardi: Financial Interests, Personal, Advisory Board: AstraZeneca, Boeringher Ingelheim, Novartis, MSD, Otsuka, Lilly, Roche, Amgen, GSK, EISAI; Financial Interests, Institutional, Funding: Roche, AstraZeneca. V. Guarneri: Financial Interests, Personal, Invited Speaker: Eli Lilly, Novartis, Amgen, GSK; Financial Interests, Personal, Advisory Board: Eli Lilly, Novartis, MSD, Gilead, Sanofi, merck serono, Exact Sciences, Eisai, Olema Oncology; Financial Interests, Personal, Expert Testimony: Eli Lilly; Financial Interests, Institutional, Invited Speaker: Eli Lilly, Roche, BMS, Novartis, AstraZeneca, MSD, Synton Biopharmaceuticals, Merck, Glaxo Smith kline, Daiichi Sankyo, Nerviano; Non-Financial Interests, Member: ASCO. G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Personal, Other, Advisory Board: Ellipsis; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, Phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Invited Speaker, Phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Invited Speaker, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Advisory Role, Member of the Scientific Council. Patient advocacy association: Europa Donna; Non-Financial Interests, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Officer, Member of the Advisory Council: EUSOMA; Non-Financial Interests, Officer, ESMO Clinical Practice Guidelines Chair: ESMO. All other authors have declared no conflicts of interest.